Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Allergy ; 68(7): 844-52, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23745779

ABSTRACT

Drug hypersensitivity may deprive patients of drug therapy, and occasionally no effective alternative treatment is available. Successful desensitization has been well documented in delayed drug hypersensitivity reactions. In certain situations, such as sulfonamide hypersensitivity in HIV-positive patients or hypersensitivity to antibiotics in patients with cystic fibrosis, published success rates reach 80%, and this procedure appears helpful for the patient management. A state of clinical tolerance may be achieved by the administration of increasing doses of the previously offending drug. However, in most cases, a pre-existent sensitization has not been proven by positive skin tests. Successful re-administration may have occurred in nonsensitized patients. A better understanding of the underlying mechanisms of desensitization is needed. Currently, desensitization in delayed hypersensitivity reactions is restricted to mild, uncomplicated exanthems and fixed drug eruptions. The published success rates vary depending on clinical manifestations, drugs, and applied protocols. Slower protocols tend to be more effective than rush protocols; however, underreporting of unsuccessful procedures is very probable. The decision to desensitize a patient must always be made on an individual basis, balancing risks and benefits. This paper reviews the literature and presents the expert experience of the Drug Hypersensitivity Interest Group of the European Academy of Allergy and Clinical Immunology.


Subject(s)
Desensitization, Immunologic/methods , Drug Hypersensitivity/diagnosis , Hypersensitivity, Delayed/chemically induced , Drug Hypersensitivity/immunology , Drug Hypersensitivity/therapy , Europe , Female , Humans , Hypersensitivity, Delayed/immunology , Hypersensitivity, Delayed/therapy , Immune Tolerance/physiology , Male , Practice Guidelines as Topic , Prognosis , Public Opinion , Skin Tests/methods , Societies, Medical/standards , Treatment Outcome
2.
Bone ; 46(6): 1486-97, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20188226

ABSTRACT

The therapeutic goal of increasing bone mass by co-treatment of parathyroid hormone (PTH) and an osteoclast inhibitor has been complicated by the undefined contribution of osteoclasts to the anabolic activity of PTH. To determine whether active osteoclasts are required at the time of PTH administration, we administered a low dose of the transient osteoclast inhibitor salmon calcitonin (sCT) to young rats receiving an anabolic PTH regimen. Co-administration of sCT significantly blunted the anabolic effect of PTH as measured by peripheral quantitative computer tomography (pQCT) and histomorphometry in the femur and tibia, respectively. To determine gene targets of sCT, we carried out quantitative real time PCR and microarray analysis of metaphyseal samples 1.5, 4 and 6.5h after administration of a single injection of PTH, sCT or PTH+sCT. Known targets of PTH action, IL-6, ephrinB2 and RANKL, were not modified by co-administration with sCT. Surprisingly, at all time points, we noted a significant upregulation of sclerostin mRNA by sCT treatment, as well as down-regulation of two other osteocyte gene products, MEPE and DMP1. Immunohistochemistry confirmed that sCT administration increased the percentage of osteocytes expressing sclerostin, suggesting a mechanism by which sCT reduced the anabolic effect of PTH. Neither mRNA for CT receptor (Calcr) nor labeled CT binding could be detected in sclerostin-enriched cells differentiated from primary calvarial osteoblasts. In contrast, osteocytes freshly isolated from calvariae expressed a high level of Calcr mRNA. Furthermore immunohistochemistry revealed co-localization of CT receptor (CTR) and sclerostin in some osteocytes in calvarial sections. Taken together these data indicate that co-treatment with sCT can blunt the anabolic effect of PTH and this may involve direct stimulation of sclerostin production by osteocytes. These data directly implicate calcitonin as a negative regulator of bone formation through a previously unsuspected mechanism.


Subject(s)
Bone Morphogenetic Proteins/genetics , Calcitonin/pharmacology , Genetic Markers/genetics , Osteocytes/metabolism , Parathyroid Hormone/pharmacology , Animals , Cells, Cultured , Computational Biology , Extracellular Matrix Proteins/genetics , Female , Femur/drug effects , Femur/metabolism , Humans , Immunohistochemistry , Interleukin-6/genetics , Mice , Mice, Inbred C57BL , Oligonucleotide Array Sequence Analysis , Osteocytes/drug effects , Phosphoproteins/genetics , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction , Tibia/drug effects , Tibia/metabolism
3.
Adv Exp Med Biol ; 658: 51-60, 2010.
Article in English | MEDLINE | ID: mdl-19950015

ABSTRACT

Members of the ephrin and Eph family are local mediators of cell function through largely contact-dependent processes in development and in maturity. Production of ephrinB2 mRNA and protein are increased by PTH and PTHrP in osteoblasts. Both a synthetic peptide antagonist of ephrinB2/EphB4 receptor interaction and recombinant soluble extracellular domain of EphB4 (sEphB4), which is an antagonist of both forward and reverse EphB4 signaling, were able to inhibit mineralization and the expression of several osteoblast genes involved late in osteoblast differentiation. The findings are consistent with ephrinB2/EphB4 signaling within the osteoblast lineage having a paracrine role in osteoblast differentiation, in addition to the proposed role of osteoclast-derived ephrinB2 in coupling of bone formation to resorption. This local regulation might contribute to control of osteoblast differentiation and bone formation at remodeling sites, and perhaps also in modeling.


Subject(s)
Cell Lineage , Ephrin-B2/metabolism , Osteoblasts/cytology , Osteoblasts/metabolism , Receptor, EphB4/metabolism , Signal Transduction , Animals , Cell Communication , Humans , Mice , Osteoclasts/cytology , Osteoclasts/metabolism , Osteogenesis , Rats
4.
J Clin Pathol ; 32(12): 1244-7, 1979 Dec.
Article in English | MEDLINE | ID: mdl-119793

ABSTRACT

Paraffin sections of a variety of tissues from 12 patients with typical hairy-cell leukaemia (HCL) were stained for immunoglobulin heavy and light chains by the peroxidase-antiperoxidase (PAP) technique. Plasma cells were frequent, particularly in a lymph node from a severely infected patient. The reactive nature of the plasma cells of HCL was suggested by the fact that there was no restriction of light-chain expression, although viable hairy cells were shown to express monoclonal surface immunoglobulin. This, together with the absence by both light and electron microscopy of forms intermediate between hairy cells and plasma cells and the lack of ribosome-lamella complexes in the plasma cells, suggested that hairy cells do not differentiate into plasma cells. Although hairy cells are known to contain immunoglobulin, this was not demonstrable in hairy cells in the paraffin-embedded tissue. The PAP technique was also useful for demonstrating abundant splenic macrophages in HCL.


Subject(s)
Immunoglobulins/analysis , Leukemia, Hairy Cell/immunology , Humans , Immunoenzyme Techniques , Immunoglobulin Heavy Chains/analysis , Immunoglobulin Light Chains/analysis , Paraffin , Plasma Cells/immunology , Spleen/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...